Katie Beauchamp, Bruce Moran, Timothy O'Brien, Donal Brennan, John Crown, Kieran Sheahan, Maura Bríd Cotter
{"title":"Carcinoma of unknown primary (CUP): an update for histopathologists.","authors":"Katie Beauchamp, Bruce Moran, Timothy O'Brien, Donal Brennan, John Crown, Kieran Sheahan, Maura Bríd Cotter","doi":"10.1007/s10555-023-10101-6","DOIUrl":null,"url":null,"abstract":"<p><p>Carcinoma of unknown primary (CUP) is a heterogeneous group of metastatic cancers in which the site of origin is not identifiable. These carcinomas have a poor outcome due to their late presentation with metastatic disease, difficulty in identifying the origin and delay in treatment. The aim of the pathologist is to broadly classify and subtype the cancer and, where possible, to confirm the likely primary site as this information best predicts patient outcome and guides treatment. In this review, we provide histopathologists with diagnostic practice points which contribute to identifying the primary origin in such cases. We present the current clinical evaluation and management from the point of view of the oncologist. We discuss the role of the pathologist in the diagnostic pathway including the control of pre-analytical conditions, assessment of sample adequacy, diagnosis of cancer including diagnostic pitfalls, and evaluation of prognostic and predictive markers. An integrated diagnostic report is ideal in cases of CUP, with results discussed at a forum such as a molecular tumour board and matched with targeted treatment. This highly specialized evolving area ultimately leads to personalized oncology and potentially improved outcomes for patients.</p>","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1189-1200"},"PeriodicalIF":7.7000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10713813/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer and Metastasis Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10555-023-10101-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Carcinoma of unknown primary (CUP) is a heterogeneous group of metastatic cancers in which the site of origin is not identifiable. These carcinomas have a poor outcome due to their late presentation with metastatic disease, difficulty in identifying the origin and delay in treatment. The aim of the pathologist is to broadly classify and subtype the cancer and, where possible, to confirm the likely primary site as this information best predicts patient outcome and guides treatment. In this review, we provide histopathologists with diagnostic practice points which contribute to identifying the primary origin in such cases. We present the current clinical evaluation and management from the point of view of the oncologist. We discuss the role of the pathologist in the diagnostic pathway including the control of pre-analytical conditions, assessment of sample adequacy, diagnosis of cancer including diagnostic pitfalls, and evaluation of prognostic and predictive markers. An integrated diagnostic report is ideal in cases of CUP, with results discussed at a forum such as a molecular tumour board and matched with targeted treatment. This highly specialized evolving area ultimately leads to personalized oncology and potentially improved outcomes for patients.
原发灶不明的癌症(CUP)是一类原发灶无法确定的转移性癌症。这些癌症的预后较差,原因是它们出现转移性疾病的时间较晚、难以确定原发部位以及治疗延误。病理学家的目的是对癌症进行大致分类和亚型,并在可能的情况下确认可能的原发部位,因为这些信息最能预测患者的预后并指导治疗。在本综述中,我们为组织病理学家提供了有助于确定此类病例原发部位的诊断要点。我们从肿瘤学家的角度介绍了当前的临床评估和管理方法。我们讨论了病理学家在诊断路径中的作用,包括分析前条件的控制、样本充分性评估、癌症诊断(包括诊断陷阱)以及预后和预测标记物的评估。综合诊断报告是 CUP 病例的理想选择,其结果可在分子肿瘤委员会等论坛上讨论,并与靶向治疗相匹配。这一高度专业化的发展领域最终会带来个性化的肿瘤学,并有可能改善患者的预后。
期刊介绍:
Contemporary biomedical research is on the threshold of an era in which physiological and pathological processes can be analyzed in increasingly precise and mechanistic terms.The transformation of biology from a largely descriptive, phenomenological discipline to one in which the regulatory principles can be understood and manipulated with predictability brings a new dimension to the study of cancer and the search for effective therapeutic modalities for this disease. Cancer and Metastasis Reviews provides a forum for critical review and discussion of these challenging developments.
A major function of the journal is to review some of the more important and interesting recent developments in the biology and treatment of malignant disease, as well as to highlight new and promising directions, be they technological or conceptual. Contributors are encouraged to review their personal work and be speculative.